Pharmaceutical

Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus A Infections: Likelihood of Approval

Influenza (quadrivalent) vaccine is under clinical development by Pfizer and currently in Phase III for Influenzavirus A Infections.

May 17, 2024 - 04:00
Influenza (quadrivalent) vaccine is under clinical development by Pfizer and currently in Phase III for Influenzavirus A Infections.
Read the original article

Tags:

Previous Article

Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus B Infections: Like...

Next Article

TT-01488 by TransThera Sciences (Nanjing) for Mantle Cell Lymphoma: Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘The drug bust paradox’: Study shows opioid deaths double after police action

‘The drug bust paradox’: Study shows opioid deaths doub...

Jun 14, 2023

Opinion: STAT+: The necessary roughness of 2023 has set up a very promising 2024 for biotech jobs

Opinion: STAT+: The necessary roughness of 2023 has set...

Jan 20, 2024

ESC 2024: Insights into RNA as therapeutic target and tool

ESC 2024: Insights into RNA as therapeutic target and tool

Sep 6, 2024